TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21747241
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg monotherapy
Study: 18794161
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 400 microg misoprostol every 3 h up to five doses
Study: 18794161
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 400 microg misoprostol every 3 h up to five doses
Study: 18794161
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 400 microg misoprostol
Study: 18794161
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 400 microg misoprostol
Study: 20560941
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration
Study: 15626947
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of DTPa-HBV-IPV/Hib and meningococcal C conjugate vaccines during the same visit
Study: 15626947
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTPa-HBV-IPV/Hib vaccine and meningococcal C conjugate vaccine
Study: 11452243
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg single oral dose in poor metabolizers
Study: 11452243
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg single oral dose in extensive metabolizers
Study: 31961489
Drug: Stepped-care intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care intervention (2-step intervention: 18-week diet and exercise program followed by 4 treatment subgroups)
Study: 25610796
Drug: Autologous cord
Normalized name: Autologous cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cord blood transfusions in conjunction with physical and occupational therapies
Study: 23681955
Drug: Allopurinol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (up to 100 mg/day)
Study: 17944983
Drug: Inhaled adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled adenosine A2A receptor agonist (GW328267X), 25 microg
Study: 12428638
Drug: Propofol target‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol target‐controlled infusion at 6 microg.ml(‐1)
Study: 7927547
Drug: T. gondii
Approvals — FDA: no, EMA: no, PMDA: no
Description: T. gondii (IgM) antibodies detection
Study: 7927547
Drug: M. hominis
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. hominis (IgG) antibodies detection
Study: 2690235
Drug: Bromhexine 30
Normalized name: bromhexine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 30 mg b.i.d. p.o.
Study: 31855922
Drug: Aspiration after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration after lavage with 500 mL physiological saline (Group II)
Study: 9722222
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy (STI) with seven preseasonal injections of tree-pollen allergens (ALK7 Frühblühermischung)
Study: 9722222
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy (STI)
Study: 8276370
Drug: Amiloride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (20 mg initial dose, increased to 60 mg/day if no response)
Study: 8276370
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (150 mg initial dose, increased to 500 mg/day if no response)
Study: 1203840
Drug: Continuous 120-hours
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 120-hours infusion of 5-fluorouracil
Study: 1203840
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 5-fluorouracil daily for 5 days
Study: 31823527
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg rasagiline tablet (single dose)
Study: 31823527
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg rasagiline transdermal patch (48-hour patch-on period)
Study: 31823527
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rasagiline transdermal patch (48-hour patch-on period)
Study: 31823527
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg rasagiline tablet (repeated doses for 7 days)
Study: 31823527
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg rasagiline transdermal patch (repeated doses every 72 hours for 5 time periods)
Study: 28436727
Drug: Polypill-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg)
Study: 28436727
Drug: Polypill-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill-based treatment
Study: 23526462
Drug: Intralipid (IL)
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (IL) infusion
Study: 21470450
Drug: Intensive hand
Normalized name: ALCOHOL 350 mL in 500 mL TOPICAL GEL [CLEAN UP Intensive Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive hand hygiene campaign (washing hands twice each day and health messages through entertainment activities)
Study: 16857049
Drug: Chronic Disease
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic Disease Self‐Management Program (CDSMP) consisting of six weekly sessions led by a CHF nurse specialist and a CHF patient.
Study: 7572943
Drug: Galvin insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galvin insulin sensitivity measure (calculated from FSIGT)
Study: 29025835
Drug: CML-enhanced maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CML-enhanced maternal milk formulation
Study: 29025835
Drug: Standard maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard maternal milk formulation
Study: 21481024
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization
Study: 17000686
Drug: Abagovomab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abagovomab 2.0 mg
Study: 17000686
Drug: Abagovomab 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abagovomab 0.2 mg
Study: 12566890
Drug: Latanoprost additive
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost additive therapy
Study: 9701293
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dihydroergotamine (DHE)
Study: 9701293
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg meperidine (MEP)
Study: 7981460
Drug: Droloxifene (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene (pooled 40 + 100 mg)
Study: 2657320
Drug: Pulsatile Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile Insulin (PI) - 75% of 32 mU/kg/h delivered as 40-second pulses every 13 minutes
Study: 2657320
Drug: Continuous Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous Insulin (CI) - 32 mU/kg/h continuous infusion
Study: 2657320
Drug: Continuous Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous Insulin (CI) - second 12 CI infusions
Study: 2657320
Drug: Pulsatile Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile Insulin (PI) followed by Continuous Insulin (CI)
Study: 2657320
Drug: Continuous Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous Insulin (CI) followed by Continuous Insulin (CI)
Study: 2657320
Drug: Pulsatile Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile Insulin (PI) - first infusion
Study: 2657320
Drug: Continuous Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous Insulin (CI) - first infusion
Study: 29030478
Drug: Early statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early statin therapy within 24 hours after admission
Study: 29030478
Drug: Delayed statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed statin therapy on the seventh day after admission
Study: 29030478
Drug: Delayed statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed statin therapy
Study: 24260889
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) with 15 Gy, preoperative chemotherapy with paclitaxel/carboplatin, and radiosensitization with cisplatin
Study: 22056385
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diazoxide
Study: 22056385
Drug: Intracerebroventricular (i.c.v.)
Normalized name: C.I. acid blue 324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracerebroventricular (i.c.v.) administration of glibenclamide
Study: 19291011
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha-2a + ribavirin 800 mg/day (Group A)
Study: 19291011
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha-2a + ribavirin 400 mg/day (Group B)
Study: 10955697
Drug: Cetirizine (antihistamine)
Normalized name: Ahist Antihistamine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine (antihistamine)
Study: 8846524
Drug: Individualized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized heparin dosing protocol with a loading dose of 50 u/kg and continuous infusion of 15 u/kg/h, adjusted with a sliding scale to target WBAPPT in the range of 150-190 seconds.
Study: 6568354
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 - monthly measurements and reinforcement of behavioral, diet, and exercise components
Study: 6568354
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 - monthly measurements
Study: 31648401
Drug: Autoimplantation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoimplantation technique every 2 weeks for a maximum of four treatments
Study: 31648401
Drug: MMR intralesional
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR intralesional injection at a dose of 0.5 ml every 2 weeks for a maximum of four treatments
Study: 31648401
Drug: MMR intralesional
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR intralesional injection
Study: 28816894
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (ORIF)
Study: 23742058
Drug: Dilute wood
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute wood smoke exposure (mean particle concentration of 314±38 μg/m3)
Study: 21284478
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at 60% of TDI
Study: 21284478
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at 80% of TDI
Study: 21284478
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine based on TDI and body weight
Study: 15514265
Drug: Pinitol supplementation
Normalized name: Fomitopsis pinicola fruiting body extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinitol supplementation (2000 mg/day)
Study: 9228438
Drug: Statin drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drugs
Study: 3305461
Drug: Ceftazidime sodium
Normalized name: Ceftazidime Sodium
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime sodium (1 or 2 g intramuscular injections, three times daily)
Study: 3305461
Drug: Ceftazidime arginine
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime arginine (1 or 2 g intramuscular injections, three times daily)
Study: 3305461
Drug: Ceftazidime sodium
Normalized name: Ceftazidime Sodium
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime sodium (1 g injections)
Study: 3305461
Drug: Ceftazidime arginine
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime arginine (1 g injections)
Study: 3305461
Drug: Ceftazidime sodium
Normalized name: Ceftazidime Sodium
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime sodium (2 g injections)
Study: 3305461
Drug: Ceftazidime arginine
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime arginine (2 g injections)
Study: 31914105
Drug: Peer specialist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer specialist services (community-based, structured curriculum for recovery, up to 40 weekly sessions)
Study: 31914105
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (case management services)
Study: 16886198
Drug: Rapid intravenous
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intravenous infusion
Study: 14644862
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment (prednisone)
Study: 10903217
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg once a day)
Study: 1891610
Drug: Patient-controlled antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled antiemetic therapy (PCAE)
Study: 1891610
Drug: Nurse-administered antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered antiemetic therapy (NCAE)
Study: 6150491
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg bromazepam daily for 3 weeks
Study: 6150491
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 3 weeks
Study: 2908134
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg bromazepam
Study: 30747551
Drug: Hydrothermally modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrothermally modified corn starch (HMS) ingestion (8% carbohydrate containing a total of 0.7 g·kg BM‐1·hr‐1; 2.8 kcal·kg BM‐1·hr‐1)
Study: 29502050
Drug: Ultrasound-guided hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided hormone injection
Study: 27138575
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg orally per day) plus Bevacizumab (15 mg/kg intravenously once every 3 weeks)
Study: 30509771
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg orally per day)
Study: 21750975
Drug: Vibration Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration Therapy (VT) - 5 sets of 1 min at 26 Hz, 6 mm peak-to-peak displacement
Study: 21750975
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no VT)
Study: 20555372
Drug: ARGININE (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARGININE (3.0 g of arginine, 300 mg of grape seed extract, and 300 mg of polyethylene glycol)
Study: 18278836
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) therapy
Study: 18278836
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) followed by Etanercept (ETN) therapy
Study: 16029070
Drug: NXY-059 (disufenton
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 (disufenton sodium) continuous intravenous infusion for 72 hours, including a 1-hour loading infusion
Study: 3171790
Drug: Dhaka solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dhaka solution with dextrose (DS + D)
Study: 3171790
Drug: Dhaka solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dhaka solution without dextrose (DS)
Study: 26106114
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (16 hours per week for 3 weeks)
Study: 26106114
Drug: Distributed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed therapy (6 hours per week for 8 weeks)
Study: 17875958
Drug: Hyperuricemia (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperuricemia (serum uric acid level, >7.0 mg/dL)
Study: 14759231
Drug: Comparators (levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparators (levofloxacin 500 mg once daily, clarithromycin 500 mg twice daily, amoxicillin/clavulanate 875/125 mg, and 1000/125 mg)
Study: 7868986
Drug: Oral estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol, 2 mg daily
Study: 7868986
Drug: Transdermal estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estradiol, 0.1 mg twice weekly
Study: 3336615
Drug: Ankle suspension
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankle suspension method
Study: 3336615
Drug: Thigh suspension
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh suspension method
Study: 3336615
Drug: Both methods
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both methods (ankle and thigh suspension)
Study: 22692502
Drug: Lysozyme-specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysozyme-specific IgE level higher than 7 kU/L
Study: 21658562
Drug: CRT-D therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D therapy (high responders)
Study: 21658562
Drug: CRT-D therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D therapy (low responders)
Study: 16684435
Drug: Prednicarbate ointment
Normalized name: Prednicarbate Ointment
DrugBank: Prednicarbate (DB01130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednicarbate ointment (Group 3)
Study: 15230485
Drug: Isoflavones (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (90 mg daily for 6 weeks)
Study: 30109588
Drug: Huannao Yicong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huannao Yicong Formula (HYF) 5 g granules twice daily
Study: 24372674
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin once a day
Study: 15361892
Drug: Nonstatin antihyperlipidaemic
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonstatin antihyperlipidaemic drug
Study: 15361892
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four antihyperlipidaemic drugs
Study: 11882512
Drug: Intravenous dideuterated
Normalized name: Deuterated water
DrugBank: Deuterium oxide (DB19251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dideuterated Delta(5)-phytosterols and oral pentadeuterated Delta(5)-phytosterols
Study: 11882512
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of soy stanols
Study: 10572324
Drug: Fluoxetine (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-60 mg)
Study: 6403172
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of ultrasonically nebulised distilled water
Study: 29365017
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (successful reperfusion)
Study: 29365017
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (successful recanalization)
Study: 26778346
Drug: Waiting, treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting, treatment, and travel time
Study: 26778346
Drug: Treatment scheme
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment scheme
Study: 25088843
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with alteplase at 0.6 mg/kg body weight
Study: 334500
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5000 IU daily, twice)
Study: 334500
Drug: Combined heparin
Normalized name: heparin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined heparin and dihydroergotamine (5000 IU heparin and 0.5 mg dihydroergotamine daily)
Study: 28657801
Drug: 20mg melatonin
Normalized name: melatonin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg melatonin gargle before each irradiation and 20mg melatonin capsules nightly during 7 weeks of concurrent chemoradiation